glp-1 agonists muscle loss Weighing the risk of treatment in older adults: Should we be concerned about sarcopenic obesity? Muscle loss and GLP-1R agonists
Description
Though the trial was powered to only detect non-inferiority, the observed (non-significant) hazard ratio for semaglutide vs
What is the pipeline for future medications for obesity
Remarkably, the 15 mg dose of tirzepatide decreased HbA1c by 2.46% and body weight by 12.4 kg at the end of the study
Taken together, GLP-1, inflammation, and the gut microbiota form a tightly interlinked feedback loop
L.CaseyC
